Status:
UNKNOWN
Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
Nanodropper, Inc.
Icare Finland Oy
Conditions:
Glaucoma
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Glaucoma is the leading cause of irreversible blindness worldwide. Previous studies demonstrate that smaller eye drops used in the treatment of glaucoma are just as efficacious as their larger counter...
Detailed Description
The proposed study strives to demonstrate the non-inferiority of using Nanodropper to lower IOP in glaucoma patients compared to standard of care (SOC) eye drops in a randomized trial. Primary Aim: D...
Eligibility Criteria
Inclusion
- 18 years old or older
- Diagnosis of open-angle glaucoma (OAG) or ocular hypertension (OHT)
- Use of prostaglandin analogue (PGA) eye drop
- Stable disease status (no visual field loss progression or increase in IOP-lowering medications in the last 6 months)
Exclusion
- Uncontrolled glaucoma
- Have had eye surgery (including laser procedures) within the past six months
- Have a diagnosis of acute angle-closure glaucoma and/or other retinal diseases
- Use of non-PGA class of IOP-lowering medication
Key Trial Info
Start Date :
October 10 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 10 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05273385
Start Date
October 10 2022
End Date
December 10 2024
Last Update
November 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Francisco
San Francisco, California, United States, 94143